514 related articles for article (PubMed ID: 17652806)
1. Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes.
Gianni L; Salvatorelli E; Minotti G
Cardiovasc Toxicol; 2007; 7(2):67-71. PubMed ID: 17652806
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant therapy for HER2 positive breast cancer: are anthracyclines still necessary?
Castrellon AB; Glück S
Clin Adv Hematol Oncol; 2008 Sep; 6(9):666-72. PubMed ID: 18827789
[TBL] [Abstract][Full Text] [Related]
3. Improving the therapeutic index of anthracycline chemotherapy: focus on liposomal doxorubicin (Myocet).
Leonard RC; Williams S; Tulpule A; Levine AM; Oliveros S
Breast; 2009 Aug; 18(4):218-24. PubMed ID: 19656681
[TBL] [Abstract][Full Text] [Related]
4. Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer.
Jensen BV
Semin Oncol; 2006 Jun; 33(3 Suppl 8):S15-21. PubMed ID: 16781285
[TBL] [Abstract][Full Text] [Related]
5. Therapy Insight: anthracyclines and trastuzumab--the optimal management of cardiotoxic side effects.
Popat S; Smith IE
Nat Clin Pract Oncol; 2008 Jun; 5(6):324-35. PubMed ID: 18364726
[TBL] [Abstract][Full Text] [Related]
6. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.
Tan-Chiu E; Yothers G; Romond E; Geyer CE; Ewer M; Keefe D; Shannon RP; Swain SM; Brown A; Fehrenbacher L; Vogel VG; Seay TE; Rastogi P; Mamounas EP; Wolmark N; Bryant J
J Clin Oncol; 2005 Nov; 23(31):7811-9. PubMed ID: 16258083
[TBL] [Abstract][Full Text] [Related]
7. 111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity.
de Korte MA; de Vries EG; Lub-de Hooge MN; Jager PL; Gietema JA; van der Graaf WT; Sluiter WJ; van Veldhuisen DJ; Suter TM; Sleijfer DT; Perik PJ
Eur J Cancer; 2007 Sep; 43(14):2046-51. PubMed ID: 17719768
[TBL] [Abstract][Full Text] [Related]
8. Cardiac toxicity of trastuzumab-related regimens in HER2-overexpressing breast cancer.
Ewer MS; O'Shaughnessy JA
Clin Breast Cancer; 2007 Jun; 7(8):600-7. PubMed ID: 17592672
[TBL] [Abstract][Full Text] [Related]
9. Reversibility of trastuzumab cardiotoxicity: is the concept alive and well?
Ewer MS; Tan-Chiu E
J Clin Oncol; 2007 Dec; 25(34):5532-3; author reply 5533-4. PubMed ID: 18048835
[No Abstract] [Full Text] [Related]
10. Trastuzumab-associated cardiotoxicity.
Keefe DL
Cancer; 2002 Oct; 95(7):1592-600. PubMed ID: 12237930
[TBL] [Abstract][Full Text] [Related]
11. The cardiac safety of trastuzumab in the treatment of breast cancer.
Chien AJ; Rugo HS
Expert Opin Drug Saf; 2010 Mar; 9(2):335-46. PubMed ID: 20175700
[TBL] [Abstract][Full Text] [Related]
12. An introduction to the metabolic determinants of anthracycline cardiotoxicity.
Menna P; Recalcati S; Cairo G; Minotti G
Cardiovasc Toxicol; 2007; 7(2):80-5. PubMed ID: 17652809
[TBL] [Abstract][Full Text] [Related]
13. Cardiotoxicity associated with the use of trastuzumab in breast cancer patients.
Perik PJ; de Korte MA; van Veldhuisen DJ; Gietema JA; Sleijfer DT; de Vries EG
Expert Rev Anticancer Ther; 2007 Dec; 7(12):1763-71. PubMed ID: 18062750
[TBL] [Abstract][Full Text] [Related]
14. Trastuzumab therapy in Australia: which patients with HER2+ metastatic breast cancer are assessed for cardiac function?
Lu CY; Srasuebkul P; Drew AK; Chen K; Ward RL; Pearson SA
Breast; 2013 Aug; 22(4):482-7. PubMed ID: 23664254
[TBL] [Abstract][Full Text] [Related]
15. Managing cardiotoxicity in anthracycline-treated breast cancers.
Ng R; Green MD
Expert Opin Drug Saf; 2007 May; 6(3):315-21. PubMed ID: 17480180
[TBL] [Abstract][Full Text] [Related]
16. Cardiotoxicity of antitumor drugs.
Menna P; Salvatorelli E; Minotti G
Chem Res Toxicol; 2008 May; 21(5):978-89. PubMed ID: 18376852
[TBL] [Abstract][Full Text] [Related]
17. Do anthracyclines still have a role in adjuvant chemotherapy of breast cancer?
Davidson A; Gelmon K
Future Oncol; 2011 Jan; 7(1):37-55. PubMed ID: 21174537
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetic-pharmacodynamic analysis of trastuzumab-associated cardiotoxicity.
van Hasselt JG; Boekhout AH; Beijnen JH; Schellens JH; Huitema AD
Clin Pharmacol Ther; 2011 Jul; 90(1):126-32. PubMed ID: 21633346
[TBL] [Abstract][Full Text] [Related]
19. Trastuzumab versus lapatinib: the cardiac side of the story.
Azim H; Azim HA; Escudier B
Cancer Treat Rev; 2009 Nov; 35(7):633-8. PubMed ID: 19640652
[TBL] [Abstract][Full Text] [Related]
20. Role of anthracyclines in the era of targeted therapy.
Cortés-Funes H; Coronado C
Cardiovasc Toxicol; 2007; 7(2):56-60. PubMed ID: 17652804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
